Coronado Biosciences, Inc. (CNDO)
-NasdaqCM 9.90 
0.17(1.69%) May 17, 4:00PM EDT
| Prev Close: | 10.07 |
|---|
| Open: | 10.12 |
|---|
| Bid: | 9.40 x 6000 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 16.09 |
|---|
| Beta: | 3.682 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 9.82 - 10.17 |
|---|
| 52wk Range: | 4.00 - 12.70 |
|---|
| Volume: | 322,120 |
|---|
| Avg Vol (3m): | 362,490 |
|---|
| Market Cap: | 249.30M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.28 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CORONADO BIOSCIENCES INC FinancialsEDGAR Online Financials(Fri, May 17)
- Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund: Investing in Health Care InnovationWall Street Transcript(Thu, May 16)
- CORONADO BIOSCIENCES INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Coronado Biosciences' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- Coronado Biosciences Reports Financial Results for the First Quarter Ended March 31, 2013GlobeNewswire(Wed, May 8)
- Q1 2013 Coronado Biosciences Earnings Release - Before Market OpenCCBN(Wed, May 8)
- CORONADO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Wed, May 8)
- Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel DiseaseGlobeNewswire(Tue, May 7)
- Coronado Biosciences to Present at the Bank of America Merrill Lynch 2013 Health Care ConferenceGlobeNewswire(Mon, May 6)
- Wall Street Transcript Interview with Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.: Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan DrugsWall Street Transcript(Wed, May 1)
- Coronado Biosciences to Report First Quarter 2013 Financial ResultsGlobeNewswire(Wed, May 1)
- Billionaire Paul Singer's Most Dramatically Built Positionsat Seeking Alpha(Mon, Apr 29)
- CORONADO BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhEDGAR Online(Mon, Apr 29)
- Coronado Biosciences Announces Departure of Dr. Bobby W. Sandage, Jr.GlobeNewswire(Wed, Apr 24)
- CORONADO BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhiEDGAR Online(Wed, Apr 24)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.31 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.32 |
|---|
| Mean Recommendation*: | 1.4 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Coronado Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunotherapy biologic agents for the treatment of autoimmune diseases and cancer.
View More